We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
New ‘Double Decker’ Antibody-drug Conjugates Fight Cancer
News

New ‘Double Decker’ Antibody-drug Conjugates Fight Cancer

New ‘Double Decker’ Antibody-drug Conjugates Fight Cancer
News

New ‘Double Decker’ Antibody-drug Conjugates Fight Cancer

Left to right: This is an image of study leaders TSRI Professor William R. Roush, Graduate Student Alex Nanna and TSRI Associate Professor Christoph Rader. Credit: The Scripps Research Institute
Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "New ‘Double Decker’ Antibody-drug Conjugates Fight Cancer "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Scientists from the Florida campus of The Scripps Research Institute (TSRI) have created a new class of antibody-drug conjugates (ADCs), using a versatile “double decker” technology that ties antibodies and a drug together to produce highly potent pharmaceuticals for cancer therapy.

The new ADC technology advances a class of pharmaceuticals that use antibodies to selectively deliver drugs to cancer cells without harming healthy cells and tissues.

The study, published online this week in the journal Nature Communications, was led by TSRI Associate Professor Christoph Rader and TSRI Professor William R. Roush.

“Our new ADCs are built something like a double-decker bus,” Rader said. “The upper deck is a targeting antibody that locks onto a cancer cell, while the lower deck is a catalytic antibody that carries the drug. This is yet another exciting application of an incredibly versatile class of catalytic antibodies originally developed by TSRI’s Carlos F. Barbas III and Richard A. Lerner in the 1990s.”

The name for this new technology is dual variable domain antibody-drug conjugates or DVD-ADCs.

Antibodies are large immune system proteins that recognize unique molecular markers on cancer cells called tumor antigens. On their own, antibodies are usually not potent enough to eradicate cancer. However, their high specificity for tumor antigens makes them ideal vehicles for drug delivery straight to cancer cells.

The new DVD-ADCs were used against HER2-driven breast cancer, as well as multiple myeloma and non-Hodgkin lymphoma, and the technology proved highly effective against all three types of cancers in both cell and animal model studies.

Not only is the new technology highly efficient, Rader explained, but it uses a modular assembly so it’s relatively simple to apply to different cancers and possibly to other diseases.

“The advantage is we can produce ADCs at a fast rate in a single step,” said Graduate Student Alex Nanna, first author of the study. “The DVD-ADC format brings everything together in a very efficient way.”

The DVD-ADCs take advantage of an unusually reactive amino acid residue, a natural lysine of the catalytic antibody. “We can tie drugs with high precision and stability to this residue and, what’s more, we can use it to monitor attachment because the antibody loses its catalytic activity when the drug attaches to the lysine. It’s a very clean and unique way to confirm successful ADC formation,” Rader said.

The technology also eliminates the need to purify the antibody during initial production, postponing that process until the ADC is assembled.  “From a manufacturing point of view, this is a substantial advantage.” Rader said.

There are currently only four FDA-approved ADCs for cancer therapy, of which two have been added this year alone.

“There is new excitement in this field,” Rader said. “One ADC was recently approved in acute lymphoblastic leukemia and there’s a rich clinical and preclinical pipeline.”

In addition to Rader, Roush and Nanna, other authors of the study, “Harnessing a catalytic lysine residue for the one-step preparation of homogeneous antibody-drug conjugates,” include TSRI’s Xiuling Li (now with Pfizer), Even Walseng (now with the National Cancer Institute), Lee Pedzisa and Rebecca S. Goydel; and David Hymel and Terrence R. Burke Jr. of the National Cancer Institute.

The study was supported by the National Institutes of Health (grant U01 CA174844), the Klorfine Foundation, the Holm Charitable Trust, the Celia Lipton Farris and Victor W. Farris Foundation and the Division of Medicinal Chemistry of the American Chemical Society.

This article has been republished from materials provided by The Scripps Research Institute (TSRI). Note: material may have been edited for length and content. For further information, please contact the cited source.

Reference

Nanna, A. R., Li, X., Walseng, E., Pedzisa, L., Goydel, R. S., Hymel, D., . . . Rader, C. (2017). Harnessing a catalytic lysine residue for the one-step preparation of homogeneous antibody-drug conjugates. Nature Communications, 8(1). doi:10.1038/s41467-017-01257-1

Advertisement